Related Experiment Video
Updated: Jun 26, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease
Patrick Weydt1, Selma M Soyal, Cinzia Gellera
1Department of Neurology, University of Ulm (P,W,; G,B,L,), Ulm, Germany. patrick.weydt@uni-ulm.de.
Huntington's disease (HD) onset is influenced by genetic factors beyond CAG repeats. Specific variants in the PGC-1alpha gene (PPARGC1A) can significantly delay disease progression in patients.
Area of Science:
- Neurogenetics
- Mitochondrial Biology
- Neurodegenerative Diseases
Background:
- Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by motor, emotional, and cognitive decline.
- Metabolic abnormalities, including wasting and altered energy expenditure, are recognized hallmarks of HD.
- HD pathogenesis involves transcriptional dysregulation, mitochondrial dysfunction, and oxidative stress, with PGC-1alpha (encoded by PPARGC1A) identified as a potentially defective regulator.
Purpose of the Study:
- To investigate the association between genetic variations in the PPARGC1A gene and the age of onset in Huntington's disease patients.
- To determine if specific haplotypes of PPARGC1A influence disease progression, independent of CAG repeat length in the HTT gene.
Main Methods:
- Analysis of 2-loci PPARGC1A block 2 haplotypes in 447 unrelated Huntington's disease patients.
- Statistical consideration of CAG repeat lengths in both HTT alleles to isolate the effect of PPARGC1A haplotypes on age-at-onset.
- Comparison of disease onset age between patients with different PPARGC1A haplotype combinations.
Main Results:
- PPARGC1A block 2 haplotypes, but not block 1 haplotypes, were associated with the age of onset in HD patients.
- Homozygosity for a specific 'protective' block 2 haplotype significantly delayed the onset of Huntington's disease.
- This finding was statistically significant after accounting for the length of CAG repeats in the HTT gene.
Conclusions:
- The PGC-1alpha system, through variations in the PPARGC1A gene, plays a clinically relevant role in modulating the age of onset for Huntington's disease in humans.
- This study provides the first evidence of a genetic modifier effect of PGC-1alpha on HD progression in a human cohort.
- Identifying genetic modifiers like PPARGC1A could offer new therapeutic targets for delaying Huntington's disease onset and progression.
Related Concept Videos
Huntington Disease l: Introduction
Genetic Lingo
Pharmacogenomics: Identification of New Drug Targets
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Alzheimer Disease ll: Pathophysiology
Cell Specific Gene Expression

